Bridgewater Associates LP Lowers Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Bridgewater Associates LP decreased its stake in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 71.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,686 shares of the health services provider's stock after selling 9,138 shares during the quarter. Bridgewater Associates LP's holdings in Amedisys were worth $335,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. XTX Topco Ltd bought a new position in Amedisys during the fourth quarter worth about $1,970,000. Barclays PLC boosted its stake in Amedisys by 333.4% in the 4th quarter. Barclays PLC now owns 67,310 shares of the health services provider's stock valued at $6,112,000 after purchasing an additional 51,781 shares during the period. Sagespring Wealth Partners LLC acquired a new position in Amedisys in the 4th quarter valued at $262,000. Water Island Capital LLC increased its position in Amedisys by 0.3% during the 4th quarter. Water Island Capital LLC now owns 603,565 shares of the health services provider's stock worth $54,798,000 after buying an additional 1,950 shares during the period. Finally, Sterling Capital Management LLC lifted its holdings in shares of Amedisys by 50.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,922 shares of the health services provider's stock worth $174,000 after buying an additional 648 shares in the last quarter. Institutional investors own 94.36% of the company's stock.

Amedisys Trading Up 0.7 %

Shares of NASDAQ:AMED traded up $0.64 during trading on Thursday, reaching $94.27. The stock had a trading volume of 464,345 shares, compared to its average volume of 403,788. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of 37.41, a P/E/G ratio of 1.78 and a beta of 0.89. The firm's fifty day moving average is $92.14 and its 200 day moving average is $91.84. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.12. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $594.78 million for the quarter, compared to analyst estimates of $597.43 million. As a group, equities analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on AMED shares. Royal Bank of Canada reissued an "outperform" rating and issued a $100.00 price objective on shares of Amedisys in a report on Wednesday, April 16th. Stephens reissued an "equal weight" rating and set a $101.00 price target on shares of Amedisys in a research report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $100.75.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.